Cellular microRNA Signatures in Multiple Sclerosis
Cellular microRNA Signatures in Multiple Sclerosis
We could not find results for this trial
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- 50 ml blodd sampling
What it measured
Main measures
microRNA expression profiles in immune cell populations from RRMS patients
2 years
Immune response
Other measures (2)
microRNA expression profiles in unstimulated and stimulated CD4+ T cell populations ex vivo from RRMS patients
2 years
Immune responsemicroRNA expression profiles in monocytes from RRMS patients
2 years
Who could take part
Relapsing MS · 18 to 60 · EDSS 1 to 6
Show the full criteria
Inclusion criteria
* Caucasian population * Female and male individuals with an f/m ratio of 2-4/1 * Individuals with RRMS according to the 2010 McDonald criteria for less than 15 years, with EDSS 1-6, in remission or relapse * Participant's condition compatible with a maximum of 50 ml of blood collection * Persons affiliated with a social security plan.
Exclusion criteria
* MS treatment with steroidal anti-inflammatory drugs, immunomodulators or immunosuppressants within 2 months prior to blood collection * Persons with acute and chronic infectious disease, autoimmune/inflammatory disease or cancer other than MS * Pregnant or lactating women * Be under guardianship, * Be deprived of liberty by judicial or administrative decision, or be under legal protection.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
A limited number of studies on microRNA expression variation in immune cells have been reported in relapsing-remitting multiple sclerosis (RRMS). These studies have been performed mostly on a small scale and on whole blood mononuclear cells (PBMC). In a number of cases, RRMS progresses to a severe secondary neurodegenerative form. In this context, it is important to look for biomarkers that could indicate the pathogenic activity of certain immune cell subpopulations.
Loading reviews and guidelines…
History
Started
Sept 2022
Main results due
Sept 2024
Finished
Sept 2024